Aclaris Therapeutics
Stock Forecast, Prediction & Price Target
Aclaris Therapeutics Financial Estimates
Aclaris Therapeutics Revenue Estimates
Aclaris Therapeutics EBITDA Estimates
Aclaris Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $6.76M N/A | $29.75M 340.05% | $31.24M 5.03% | Avg: $10.67M Low: $10.67M High: $10.67M avg. -65.82% | Avg: $7.36M Low: $7.36M High: $7.36M avg. -31.04% | Avg: $14.72M Low: $14.72M High: $14.72M avg. 99.89% | Avg: $37.49M Low: $37.49M High: $37.49M avg. 154.74% |
Net Income
% change YoY
| $-90.86M N/A | $-86.90M 4.35% | $-88.48M -1.80% | Avg: $-43.90M Low: $-43.90M High: $-43.90M avg. 50.38% | Avg: $-41.60M Low: $-41.60M High: $-41.60M avg. 5.22% | Avg: $-43.97M Low: $-43.97M High: $-43.97M avg. -5.70% | Avg: $-26.29M Low: $-26.29M High: $-26.29M avg. 40.21% |
EBITDA
% change YoY
| $-64.46M N/A | $-84.35M -30.86% | $-87.98M -4.30% | Avg: $-10.67M Low: $-10.67M High: $-10.67M avg. 87.86% | Avg: $-7.36M Low: $-7.36M High: $-7.36M avg. 31.04% | Avg: $-14.72M Low: $-14.72M High: $-14.72M avg. -99.89% | Avg: $-37.49M Low: $-37.49M High: $-37.49M avg. -154.74% |
EPS
% change YoY
| -$1.6 N/A | -$1.33 16.87% | -$1.27 4.51% | Avg: -$0.63 Low: -$0.63 High: -$0.63 avg. 50.48% | Avg: -$0.6 Low: -$0.6 High: -$0.6 avg. 5.22% | Avg: -$0.63 Low: -$0.63 High: -$0.63 avg. -5.70% | Avg: -$0.38 Low: -$0.38 High: -$0.38 avg. 40.21% |
Operating Expenses
% change YoY
| $67.43M N/A | $102.94M 52.66% | $12.14M -88.20% | Avg: $31.78M Low: $31.78M High: $31.78M avg. 161.81% | Avg: $21.91M Low: $21.91M High: $21.91M avg. -31.04% | Avg: $43.81M Low: $43.81M High: $43.81M avg. 99.89% | Avg: $111.62M Low: $111.62M High: $111.62M avg. 154.74% |
FAQ
What is Aclaris Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 22.52% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is -43.90M, average is -43.90M and high is -43.90M.
What is Aclaris Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 39.44% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is $10.67M, average is $10.67M and high is $10.67M.
What is Aclaris Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 22.55% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is -$0.63, average is -$0.63 and high is $-0.62.